Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [Spatial Transcriptome seq]

ABSTRACT: Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [Spatial Transcriptome seq]

PROVIDER: PRJNA1058423 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27372455_1.fastq.gz	Fastqsanger.gz
	SRR27372455_2.fastq.gz	Fastqsanger.gz
	SRR27372456_1.fastq.gz	Fastqsanger.gz
	SRR27372456_2.fastq.gz	Fastqsanger.gz
	SRR27372457_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [scRNA-seq]

Project description:Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [scRNA-seq]

| PRJNA1058410 | ENA

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [scRNA-seq]

Project description:We thoroughly analyzed the molecular subtyping of Triple-Negative Breast Cancer and its different manifestations, and located T cells and Tumor cells related to the survival of breast cancer through single cell sequencing and space transcriptome according to our score, and finally investigated their relationship with the therapeutic efficacy, providing a scientific basis for the treatment of triple negative breast cancer.

2024-05-17 | GSE252175 | GEO

Multi-Omics molecular subtyping based on commensal microbiome predicts molecular characteristics and therapeutic response in Triple-Negative Breast Cancer [Spatial Transcriptome seq]

2024-05-17 | GSE252176 | GEO

Molecular subtyping of breast cancer by transcription profiling

Project description:Breast cancer was one of the first cancer types where molecular subtyping led to explanation of interpersonal heterogeneity and resulted in improvement of treatment regimen. Several multigene classifiers have been developed and in particular those defining molecular signatures of early breast cancers possess significant prognostic information. Hence since 2014, molecular subtyping of primary breast cancers was implemented as a part of routine diagnostics with direct impact of therapy assignment. In this study, we evaluate direct and potential benefits of molecular subtyping in low-risk breast cancers as well as present the advantages of a robust molecular signature in regard to patient work-up among high-risk breast cancers.

2017-12-01 | E-MTAB-5724 | biostudies-arrayexpress

Colorectal Adenomas and Consensus Molecular Subtyping

Project description:Consensus molecular subtyping in adenomatous and serrated polyps

2018-12-19 | GSE108317 | GEO

Colorectal Adenomas and Consensus Molecular Subtyping

Project description:Colorectal Adenomas and Consensus Molecular Subtyping

| PRJNA423096 | ENA

Molecular subtyping of “double negative” MIBC

Project description:Molecular subtyping of “double negative” MIBC

| PRJNA816119 | ENA

Gene-expression molecular subtyping of triple-negative breast cancer tumors

Project description:Gene-expression molecular subtyping of triple-negative breast cancer tumors

| PRJNA400182 | ENA

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping

Project description:Triple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer with limited options for therapy. TNBC is a heterogeneous disease and tumours has been classified into TNBC subtypes using gene expression profiling to distinguish basal-like1 (BL1), basal-like2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal/stem-like (MSL), luminal androgen receptor (LAR) and one non-classifiable group (called unstable, UNS). The aim of this study was to verify the clinical relevance of molecular subtyping of TNBCs by expression analysis to improve the individual indication of systemic therapy.

2021-07-31 | GSE167213 | GEO

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping

Project description:Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping

| PRJNA703939 | ENA